Bristol-Myers Squibb (BMY) Holdings Reduced by Timber Hill LLC

Timber Hill LLC reduced its holdings in Bristol-Myers Squibb (NYSE:BMY) by 24.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 43,777 shares of the biopharmaceutical company’s stock after selling 13,950 shares during the period. Timber Hill LLC’s holdings in Bristol-Myers Squibb were worth $2,769,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. BlackRock Inc. increased its position in Bristol-Myers Squibb by 5.0% in the 4th quarter. BlackRock Inc. now owns 104,293,294 shares of the biopharmaceutical company’s stock worth $6,391,093,000 after buying an additional 4,945,515 shares during the period. Geode Capital Management LLC increased its position in Bristol-Myers Squibb by 4.4% in the 4th quarter. Geode Capital Management LLC now owns 18,583,469 shares of the biopharmaceutical company’s stock worth $1,136,568,000 after buying an additional 777,929 shares during the period. Renaissance Technologies LLC increased its position in Bristol-Myers Squibb by 31.9% in the 4th quarter. Renaissance Technologies LLC now owns 14,302,900 shares of the biopharmaceutical company’s stock worth $876,482,000 after buying an additional 3,456,300 shares during the period. TIAA CREF Investment Management LLC increased its position in Bristol-Myers Squibb by 30.8% in the 4th quarter. TIAA CREF Investment Management LLC now owns 10,932,722 shares of the biopharmaceutical company’s stock worth $669,957,000 after buying an additional 2,573,967 shares during the period. Finally, Legal & General Group Plc increased its position in Bristol-Myers Squibb by 2.3% in the 3rd quarter. Legal & General Group Plc now owns 8,622,652 shares of the biopharmaceutical company’s stock worth $549,588,000 after buying an additional 191,304 shares during the period. 71.49% of the stock is currently owned by institutional investors.

Shares of BMY stock opened at $52.71 on Friday. The company has a current ratio of 1.52, a quick ratio of 1.39 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $86.21 billion, a P/E ratio of 17.51, a P/E/G ratio of 1.32 and a beta of 0.99. Bristol-Myers Squibb has a one year low of $49.96 and a one year high of $70.05.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, April 26th. The biopharmaceutical company reported $0.94 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.85 by $0.09. The business had revenue of $5.19 billion for the quarter, compared to analyst estimates of $5.25 billion. Bristol-Myers Squibb had a return on equity of 37.56% and a net margin of 4.37%. Bristol-Myers Squibb’s quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.84 EPS. research analysts expect that Bristol-Myers Squibb will post 3.41 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Tuesday, May 1st. Investors of record on Friday, April 6th were paid a $0.40 dividend. This represents a $1.60 annualized dividend and a yield of 3.04%. The ex-dividend date was Thursday, April 5th. Bristol-Myers Squibb’s dividend payout ratio is 53.16%.

BMY has been the topic of several recent analyst reports. Jefferies Group set a $72.00 price target on Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Monday, February 26th. Bank of America lifted their price target on Bristol-Myers Squibb from $64.00 to $68.00 and gave the stock a “neutral” rating in a research report on Monday, March 5th. Zacks Investment Research raised Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research report on Friday, January 19th. Vetr downgraded Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $60.72 price target on the stock. in a research report on Thursday, February 8th. Finally, Barclays lowered their price objective on Bristol-Myers Squibb from $65.00 to $55.00 and set an “equal weight” rating on the stock in a research report on Friday, April 27th. Three analysts have rated the stock with a sell rating, twelve have issued a hold rating and eight have given a buy rating to the stock. Bristol-Myers Squibb has an average rating of “Hold” and a consensus target price of $63.68.

In related news, Director Dinesh C. Paliwal purchased 4,770 shares of the firm’s stock in a transaction that occurred on Monday, April 30th. The shares were acquired at an average price of $52.40 per share, with a total value of $249,948.00. Following the purchase, the director now directly owns 8,027 shares in the company, valued at $420,614.80. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.23% of the stock is owned by insiders.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply